Opthea Completes Drug Product PPQ Campaign
Three consecutive commercial-scale drug product batches successfully produced Supports potential sozinibercept BLA filing in 1H CY2026 MELBOURNE, ...
GlobalData on MSN13h
Inceptor Bio doses first subject in trial of IB-T101 for renal cell carcinoma
US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead ...
ophthalmologyadvisor8h
Retinal Gene Therapy Options Advance Through Clinical Trial Investigations
Retinal gene therapy advancements may rewrite the book on treatments for age-related macular degeneration and diabetic eye diseases.
PipelineReview.com18h
Inceptor Bio Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma (ccRCC) and $21M Series A2 Financing
RESEARCH TRIANGLE PARK, NC, USA I5, 2025 I Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
ZME Science on MSN7h
Doctors Restore Sight in Blind Children with Groundbreaking Gene Therapy
A single injection of a healthy gene allowed blind children to recognize objects, shapes, and even read — offering hope for ...
PipelineReview.com18h
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
PASADENA, CA, USA I February 25, 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s ...